Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6751 to 6765 of 7691 results

  1. Vandetanib for treating metastatic, differentiated thyroid cancer refractory to or unsuitable for radioiodine therapy [ID907]

    Discontinued [GID-TA11259]

    Technology appraisal guidance
    Discontinued

  2. Bavituximab for treating non-squamous non-small-cell lung cancer after platinum-based chemotherapy [ID975]

    Discontinued [GID-TA11260]

    Technology appraisal guidance
    Discontinued

  3. Triptorelin for the adjuvant treatment of early breast cancer in premenopausal women [ID976]

    Discontinued [GID-TA11261]

    Technology appraisal guidance
    Discontinued

  4. Ataluren for treating cystic fibrosis in people with a CFTR gene nonsense mutation [ID955]

    Discontinued [GID-TA11262]

    Technology appraisal guidance
    Discontinued

  5. ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]

    Discontinued [GID-TA10259]

    Technology appraisal guidance
    Discontinued

  6. Nilotinib for the first line treatment of chronic myeloid leukaemia [ID79]

    Discontinued [GID-TAG408]

    Technology appraisal guidance
    Discontinued

  7. Psoriatic arthritis (moderate to severe) - leflunomide [ID391]

    Discontinued [GID-TAG385]

    Technology appraisal guidance
    Discontinued

  8. Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

    In development [GID-TA10575] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Diabetic retinopathy - ruboxistaurin [ID382]

    In development [GID-TAG386] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Atrial fibrillation - idraparinux sodium [ID375]

    Discontinued [GID-TAG383]

    Technology appraisal guidance
    Discontinued

  11. Cardiovascular events (prevention, high risk) - anacetrapib [ID1164]

    Discontinued [GID-TA11176]

    Technology appraisal guidance
    Discontinued

  12. Osteoarthritis - diacerein [ID332]

    Discontinued [GID-TAG250]

    Technology appraisal guidance
    Discontinued

  13. Nivolumab monotherapy for non-small-cell lung cancer [ID1088]

    Discontinued [GID-TA10148]

    Technology appraisal guidance
    Discontinued

  14. Multiple sclerosis (primary-progressive) - fingolimod [ID62]

    Discontinued [GID-TAG221]

    Technology appraisal guidance
    Discontinued

  15. Human Growth Hormone for Idiopathic Short Stature (in children)[ID317]

    Discontinued [GID-TA11256]

    Technology appraisal guidance
    Discontinued